Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) have earned an average rating of "Moderate Buy" from the six ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $6.25.

A number of research analysts have recently weighed in on the company. Wall Street Zen cut Xeris Biopharma from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Craig Hallum raised their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a report on Friday, March 7th. Piper Sandler restated a "neutral" rating and set a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Oppenheimer upped their price target on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Finally, Leerink Partners raised their price objective on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a research note on Friday, March 7th.

Xeris Biopharma Stock Performance

XERS traded down $0.01 on Friday, hitting $4.66. 2,301,916 shares of the company were exchanged, compared to its average volume of 2,033,232. Xeris Biopharma has a fifty-two week low of $2.03 and a fifty-two week high of $6.07. The firm has a market capitalization of $728.73 million, a P/E ratio of -15.53 and a beta of 0.67. The business's fifty day moving average is $4.66 and its 200 day moving average is $4.22.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The firm had revenue of $57.80 million during the quarter, compared to analyst estimates of $57.61 million. Analysts forecast that Xeris Biopharma will post -0.41 EPS for the current fiscal year.

Insider Transactions at Xeris Biopharma

In other news, insider Kevin Mcculloch purchased 25,000 shares of the firm's stock in a transaction on Friday, June 13th. The shares were bought at an average cost of $4.38 per share, with a total value of $109,500.00. Following the purchase, the insider directly owned 1,708,585 shares of the company's stock, valued at approximately $7,483,602.30. This trade represents a 1.48% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.56% of the company's stock.

Hedge Funds Weigh In On Xeris Biopharma

Institutional investors and hedge funds have recently modified their holdings of the company. R Squared Ltd grew its stake in Xeris Biopharma by 27.7% in the 1st quarter. R Squared Ltd now owns 15,730 shares of the company's stock worth $86,000 after acquiring an additional 3,410 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Xeris Biopharma by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company's stock worth $273,000 after purchasing an additional 3,447 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Xeris Biopharma by 31.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company's stock worth $55,000 after purchasing an additional 3,847 shares during the last quarter. Apollon Wealth Management LLC boosted its holdings in shares of Xeris Biopharma by 19.8% during the first quarter. Apollon Wealth Management LLC now owns 24,160 shares of the company's stock worth $133,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Prudential Financial Inc. grew its position in shares of Xeris Biopharma by 23.4% in the fourth quarter. Prudential Financial Inc. now owns 36,945 shares of the company's stock valued at $125,000 after purchasing an additional 7,000 shares during the period. Hedge funds and other institutional investors own 42.75% of the company's stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.